Commentary on using the SF-36 or MOS-HIV in studies of persons with HIV disease
about
Effectiveness of aerobic exercise for adults living with HIV: systematic review and meta-analysis using the Cochrane Collaboration protocolThe economic costs and health-related quality of life of people with HIV/AIDS in the Canary Islands, Spain.HIV and COPD: impact of risk behaviors and diseases on quality of life.Sexual relationship power and depression among HIV-infected women in Rural UgandaA comparison of the MOS-HIV and SF-12v2 for measuring health-related quality of life of men and women living with HIV/AIDSRelationship of depression and catastrophizing to pain, disability, and medication adherence in patients with HIV-associated sensory neuropathy.Chronic illness burden and quality of life in an aging HIV population.Quality of life profile and psychometric properties of the EQ-5D-5L in HIV/AIDS patientsSocial and behavioral science in HIV vaccine trials: a gap assessment of the literature.Adverse quality of life consequences of antiretroviral medications.Use of Western Neuropsychological Test Battery in Detecting HIV-Associated Neurocognitive Disorders (HAND) in Zambia.The relationships among social support and quality of life in persons living with HIV/AIDS in Jiangxi and Zhejiang provinces, China.Formulation preference, tolerability and quality of life assessment following a switch from lopinavir/ritonavir soft gel capsule to tablet in human immunodeficiency virus-infected patients.Effect of Methadone Dose on Maintenance Treatment and Health Consequences Among Heroin Addicts in South China.
P2860
Q28069512-306C6821-1727-4087-855E-5EAD3CAAFB9FQ33424079-FF8B2160-A111-484C-8913-5DC306634B7CQ33898001-70D99A0D-034C-41C3-A593-044E88F1B223Q34539991-1B530EC2-2AF6-4283-B2C1-AD9FDF036C84Q34573642-0AA5A5E4-3C47-4C0F-8416-0527646A1C3AQ35565643-19269308-B306-4FA3-92DA-152EF0677219Q36504074-B90597DE-0C73-4A6F-BACF-2647714B6F43Q36521187-BFF013B4-877F-48F4-A375-D3BAA17F211BQ37386288-FA2B568F-F326-43E2-9A78-90C89DA1F8F7Q40233430-B8914A44-0E75-4814-AA64-5C0762BD2EA2Q40640105-1D72E0CB-D140-4396-984B-2F0CCDE6DBF5Q41471416-04AC4B2D-5EF2-4A89-8B4C-F25EA64DBBFAQ42933928-537C72A0-CF7E-4763-ADA7-16DF5879C146Q43455388-7A940808-1DFA-4E99-A297-CD5F900B289A
P2860
Commentary on using the SF-36 or MOS-HIV in studies of persons with HIV disease
description
2003 nî lūn-bûn
@nan
2003 թուականին հրատարակուած գիտական յօդուած
@hyw
2003 թվականին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Commentary on using the SF-36 or MOS-HIV in studies of persons with HIV disease
@ast
Commentary on using the SF-36 or MOS-HIV in studies of persons with HIV disease
@en
Commentary on using the SF-36 or MOS-HIV in studies of persons with HIV disease
@nl
type
label
Commentary on using the SF-36 or MOS-HIV in studies of persons with HIV disease
@ast
Commentary on using the SF-36 or MOS-HIV in studies of persons with HIV disease
@en
Commentary on using the SF-36 or MOS-HIV in studies of persons with HIV disease
@nl
prefLabel
Commentary on using the SF-36 or MOS-HIV in studies of persons with HIV disease
@ast
Commentary on using the SF-36 or MOS-HIV in studies of persons with HIV disease
@en
Commentary on using the SF-36 or MOS-HIV in studies of persons with HIV disease
@nl
P2093
P2860
P3181
P356
P1476
Commentary on using the SF-36 or MOS-HIV in studies of persons with HIV disease
@en
P2093
Jim Shahriar
Ron D Hays
Stephen Joel Coons
Thomas Delate
P2860
P2888
P3181
P356
10.1186/1477-7525-1-25
P407
P577
2003-01-01T00:00:00Z
P5875
P6179
1030906347